
© 2025 sharedeals.de
Realtime | Geld | Brief | Zeit |
---|---|---|---|
29,760 | 30,320 | 13:03 | |
30,130 | 30,510 | 16.05. |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Mi | BridgeBio Pharma, Inc.: BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today... ► Artikel lesen | |
Mi | Why BridgeBio Pharma, Inc. (BBIO) Declined on Tuesday | ||
Di | BridgeBio launches landmark ATTR prevention study | ||
Di | BridgeBio Pharma, Inc.: First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study | - ATTRibute-CM, BridgeBio's Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients... ► Artikel lesen | |
Mo | BridgeBio Pharma, Inc.: BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association ... |